Filing Flows › Nuvation Bio (NUVB) › Q2 2025
Nuvation Bio (NUVB) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Nuvation Bio (NUVB) reported revenue of $4.8M for the second quarter 2025 (Q2 2025), +237% from a year earlier and +57% from the quarter before.
Nuvation Bio, Q2 2025: revenue $4.8M (+237% year over year), net loss $59.0M, operating cash flow −$48.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.8M | +57% | +237% |
| Operating profit | −$63.6M | — | — |
| Net earnings | −$59.0M | — | — |
| Operating cash flow | −$48.2M | — | — |
What changed
Revenue was $4.8M in Q2 2025, up 237% year over year and up 57% from the previous quarter. License was the largest line at 74% of revenue. License added $2.2M year over year (up 151%), 64% of the total change.
Gross margin was 46.7%, up 40.6 points from a year earlier. Operating costs exceeded revenue by $63.6M, an operating margin of -1315.7%. Operating expenses fell 86% while revenue rose 237%. The fastest-growing cost line was SG&A (+138%). The quarter ended with a net loss of $59.0M, wider than the previous quarter's $53.2M loss.
Operating cash flow was −$48.2M. Non-cash charges added back $356K of depreciation and amortization and $12.0M of share-based compensation.
Questions
What was Nuvation Bio's revenue in the second quarter 2025?
Nuvation Bio (NUVB) reported revenue of $4.8M for the second quarter 2025 (Q2 2025), +237% from a year earlier and +57% from the quarter before.
Source: Nuvation Bio 10-Q on SEC EDGAR.